{"nct_id":"NCT05508906","title":"Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, or Everolimus in ER+, HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-08","start_date":"2022-08-31","start_date_type":"ACTUAL","primary_completion_date":"2026-08-09","primary_completion_date_type":"ESTIMATED","completion_date":"2026-09-09","completion_date_type":"ESTIMATED","phases":["PHASE1"],"tickers":["OLMA"]}